We enrolled treatment-naive patients with drug-susceptible , pulmonary tuberculosis , who were randomly assigned by computer-generated sequences to receive either @ weeks of moxifloxacin , @ mg pretomanid ( formerly known as PA-@ ) , and pyrazinamide ( MPa@Z regimen ) ; moxifloxacin , @ mg pretomanid , and pyrazinamide ( MPa@Z regimen ) ; or the current standard care for drug-susceptible pulmonary tuberculosis , isoniazid , rifampicin , PZA , and ethambutol ( HRZE regimen ) .